Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2021–2024

INTERCEPT-MDS · Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2021-01-01 → 2024-12-31
Финансиране от ЕС
3 120 456 €
Участници
10
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Миелоидните заболявания, като остра левкемия, се изследват чрез анализ на отделни клетки, за да се открият болните, преди заболяването да се развие напълно. Това е важно, за да се подобрят шансовете за оцеляване и клиничните резултати при пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.

Promoting healthy aging is a global goal from the European Commission. Acute myeloid leukaemia (AML) is the most common type of acute leukaemia in adults and myelodysplastic syndrome (MDS) is the most frequent hematopoietic disorder of the elderly. Due to limited treatment options, the overall 5-year survival rate is less than 30%. These disorders remain among the most devastating cancers worldwide. Disease interception is a novel concept referring to treatment of a disease before it fully develops by removing altered cells. Ideally, diseases could be intercepted and removed from the body during an asymptomatic stage of the disease, and the disease would never develop. However, the identification and specific targeting of diseased cells amongst a population of healthy cells without side effects remains a challenge. The EU-funded INTERCEPT-MDS project establishes a multidisciplinary training programme to provide early-stage researchers with the necessary expertise in the field. The project gathers pan-European experts and experienced trainers from two sectors (academia and industry) and two research environments (clinic and basic) to make this possible. Thus, INTERCEPT-MDS’ global goal is to promote healthy aging by approaching the disease cell interception, providing human capital, establish durable links between leading organisations and cross-fertilization between sectors. The project is expected to advance the field of disease interception and improve the clinical outcome of myeloid diseases. From a scientific perspective, the project focuses on myeloid diseases and uses single-cell state-of-the-art methodologies to develop novel research tools that can help identify clonally distinct cells. INTERCEPT-MDS’ scientific questions and objectives are tackled by three independent but interconnected work packages (WP): WP1 – Identification of disease cells; WP2 - Exploring and exploiting epigenetics for interception; WP3 - Models and tools for disease cell detection and interception. INTERCEPT-MDS’ training objectives are to: 1) train in state-of-the-art knowledge of myeloid diseases and epigenetic regulation to advance on the development of disease cell interception strategies; 2) transmit the skills to leverage latest technologies; 3) provide early-stage researchers with a toolset of transferable skills and a network of peers that will allow them to successfully develop their careers in any sector; 4) provide a personalized and tailored training maximizing individual career perspectives.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Disease interception is a novel concept referring to treatment of a disease before the disease fully develops by removing altered cells. To make disease cell interception a reality we will need to overcome two key challenges. First, we will need to be able to identify few altered disease cells among many healthy ones. Second, we need to develop strategies that allow to specifically target disease cells but do not affect healthy cells. In the INTERCEPT-MDS ITN we propose to approach these challenges through research and the shared multidisciplinary and multisectorial training of 12 Early Stage Researchers (ESRs). As a result we will build and present some of Europe’s first experts in the novel field of disease cell interception. We will take advantage of single-cell omics methods that have reached a level of maturity to be applied on a broad-scale. For interception, we will explore and exploit the epigenetic regulatory space and use our privileged access to tool compounds and our capacity to perform genetic screenings in vivo and in vitro. We will focus on myeloid diseases because they are a suitable paradigm for clonally evolving diseases and come with a major advantage. In contrast to most other diseases is the availability of stem cells, niche cells and their progeny through samples of the clinical routine. Finally, we will address technical challenges by developing novel research tools.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз